Concerns for Development After Bevacizumab Treatment of ROP

Pediatrics. 2016 Apr;137(4):e20160057. doi: 10.1542/peds.2016-0057. Epub 2016 Mar 17.

Authors

Graham E Quinn¹, Brian A Darlow²

Affiliations

¹ Division of Ophthalmology, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; and quinn@email.chop.edu.
² Department of Paediatrics, University of Otago, Christchurch, New Zealand.

PMID: 27244707
DOI: 10.1542/peds.2016-0057

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Bevacizumab*
Gestational Age
Humans
Intravitreal Injections
Retinopathy of Prematurity*

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab